Innocan Pharma Corporation (TSE:INNO) has released an update.
Innocan Pharma Corporation has announced a significant advancement in the pharmaceutical industry by initiating the FDA approval process for its innovative LPT-CBD drug delivery technology, moving closer to achieving pharmaceutical-grade product status. The company has signed an agreement with the Hebrew University to meet FDA Chemistry Manufacturing Control (CMC) guidelines for its liposome CBD platform, marking a critical step towards clinical and marketing phases.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
